Categories AlphaGraphs, Consumer, Earnings
EL Earnings: Highlights of Estee Lauder’s Q4 2023 financial report
Estee Lauder Companies Inc. (NYSE: EL) announced financial results for the fourth quarter of 2023, reporting modest revenue growth and lower adjusted earnings.
First-quarter net sales edged up 1% annually to $3.61 billion. A decline in the core Skin Care segment was more than offset by growth in the other areas of the business.
Adjusted earnings, excluding one-off items, declined sharply to $0.07 per share in Q4 from $0.42 per share in the fourth quarter of 2022. On an unadjusted basis, the company reported a net loss of $33 million or $0.09 per share, compared to a profit of $52 million or $0.14 per share last year.
Fabrizio Freda, the company’s CEO, said, “We returned to organic sales growth in the fourth quarter, delivering our outlook. Momentum continued in the markets of EMEA and Latin America, and accelerated strongly in Asia/Pacific led by mainland China and Hong Kong SAR.”
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
